Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Venus Remedies now has 29 active product approvals in Vietnam alone
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated
